Skip to main content
SpringerLink
Log in

Prognostic significance of metabolic parameters measured by 18F-FDG PET/CT in limited-stage small-cell lung carcinoma

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Metabolic parameters measured by [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) are important prognostic factors in several types of cancers. We evaluated the predictive value of tumor metabolic parameters measured by 18F-FDG PET/CT in limited-disease small-cell lung cancer (LD-SCLC).

Methods

This retrospective study included 30 LD-SCLC patients who underwent standard chemotherapy after radiotherapy with 18F-FDG PET/CT. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and blood glucose-corrected values were used to evaluate metabolic parameters in primary tumors.

Results

For the median follow-up of 41.1 months, median overall survival (OS) was 75.0 months [95% confidence interval (CI) 20.9–129.1 months], and median progression-free survival (PFS) was 9.5 months (95% CI 6.8–12.1 months). Two-year OS was 78.6%, and PFS was 32.7%. OS analysis indicated that MTV and TLG were significant predictors of OS following standard treatment. High glucose-corrected SUVmax (glu-SUVmax) was related to shorter median PFS. On multivariate analysis, MTV was an independent factor of OS, and glu-SUVmax was significantly related to PFS.

Conclusions

MTV and glu-SUVmax measured on pretreatment 18F-FDG PET/CT were independent prognostic factors for LD-SCLC patients after chemoradiotherapy with curative intent. These metabolic markers need validation in larger prospective studies but may be useful in the clinical care of LD-SCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Azad A, Chionh F, Scott AM, Lee ST, Berlangieri SU, White S, Mitchell PL (2010) High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol 12(4):443–451

    Article  PubMed  Google Scholar 

  • Braun DP, Gupta D, Staren ED (2011) Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC Cancer 11:353

    Article  PubMed  PubMed Central  Google Scholar 

  • Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, Henke M, Ghanem N, Moser E, Nitzsche EU (2004) Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 31(12):1614–1620

    Article  CAS  PubMed  Google Scholar 

  • Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM (2012) 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med 53(5):709–715

    Article  CAS  PubMed  Google Scholar 

  • Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, Lee JS (2005) Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol 23(15):3488–3494

    Article  CAS  PubMed  Google Scholar 

  • Jiang W, Bi N, Zhang WJ et al (2016) MicroRNA-related polymorphisms in apoptosis pathway genes are predictive of clinical outcome in patients with limited disease small cell lung cancer. Oncotarget 7(16):22632–22638

    PubMed  PubMed Central  Google Scholar 

  • Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC (2003) Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 44(12):1911–1917

    PubMed  Google Scholar 

  • Langen KJ, Braun U, Rota Kops E, Herzog H, Kuwert T, Nebeling B, Feinendegen LE (1993) The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 34(3):355–359

    CAS  PubMed  Google Scholar 

  • Lee WW, Chung JH, Jang SJ, Eo JS, Park SY, Sung SW, So Y, Chung JK, Lee MC, Kim SE (2006) Consideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PET. J Surg Oncol 94(7):607–613

    Article  CAS  PubMed  Google Scholar 

  • Lee YJ, Cho A, Cho BC, Yun M, Kim SK, Chang J, Moon JW, Park IK, Choi HJ, Kim JH (2009) High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 15(7):2426–2432

    Article  CAS  PubMed  Google Scholar 

  • Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, Ahn MJ, Kim TS, Yi CA, Chung MJ (2010) Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 17(10):2787–2794

    Article  PubMed  Google Scholar 

  • Lee SM, Kim TS, Lee JW, Kim SK, Park SJ, Han SS (2011) Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET. Clin Nucl Med 36(5):331–336

    Article  PubMed  Google Scholar 

  • Lee JW, Kang CM, Choi HJ, Lee WJ, Song SY, Lee JH, Lee JD (2014) Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative (1)(8)F-FDG PET/CT in patients with pancreatic cancer. J Nucl Med 55(6):898–904

    Article  CAS  PubMed  Google Scholar 

  • Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H (1993) Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. J Nucl Med 34(1):1–6

    CAS  PubMed  Google Scholar 

  • Lodge MA, Chaudhry MA, Wahl RL (2012) Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med 53(7):1041–1047

    Article  CAS  PubMed  Google Scholar 

  • Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, Buhl R (2002) Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? Lung Cancer 37(3):271–276

    Article  PubMed  Google Scholar 

  • Nahmias C, Wahl LM (2008) Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med 49(11):1804–1808

    Article  PubMed  Google Scholar 

  • Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, Bom HS (2012) Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging 39(6):925–935

    Article  PubMed  Google Scholar 

  • Onitilo AA, Engel JM, Demos JM, Mukesh B (2008) Prognostic significance of 18 F-fluorodeoxyglucose—positron emission tomography after treatment in patients with limited stage small cell lung cancer. Clin Med Res 6(2):72–77

    Article  PubMed  PubMed Central  Google Scholar 

  • Osterlind K (2000) LDH or NSE or LDH and NSE as pretreatment prognostic factors in small cell lung cancer? A commentary. Lung Cancer 30(1):51–53

    Article  CAS  PubMed  Google Scholar 

  • Pandit N, Gonen M, Krug L, Larson SM (2003) Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 30(1):78–84

    Article  PubMed  Google Scholar 

  • Park SB, Choi JY, Moon SH, Yoo J, Kim H, Ahn YC, Ahn MJ, Park K, Kim BT (2014) Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging 14:2

    PubMed  PubMed Central  Google Scholar 

  • Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108

    Article  PubMed  Google Scholar 

  • Pignon JP, Arriagada R, Ihde DC et al (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327(23):1618–1624

    Article  CAS  PubMed  Google Scholar 

  • Ready NE, Pang HH, Gu L et al (2015) Chemotherapy with or without maintenance Sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol 33(15):1660–1665

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Seol YM, Kwon BR, Song MK et al (2010) Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 49(2):201–208

    Article  CAS  PubMed  Google Scholar 

  • Simon M, Argiris A, Murren JR (2004) Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 49(2):119–133

    Article  PubMed  Google Scholar 

  • Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48(6):932–945

    Article  PubMed  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

    Article  CAS  PubMed  Google Scholar 

  • Yamamoto Y, Kameyama R, Murota M, Bandoh S, Ishii T, Nishiyama Y (2009) Early assessment of therapeutic response using FDG PET in small cell lung cancer. Mol Imaging Biol 11(6):467–472

    Article  CAS  PubMed  Google Scholar 

  • Yip D, Harper PG (2000) Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 28(3):173–185

    Article  CAS  PubMed  Google Scholar 

  • Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J (2011) Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer 73(3):332–337

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Hyun Chang and Soo Jin Lee contributed equally to this work as co-first authors.

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea

    Hyun Chang, Jong Seok Lee & Yu Jung Kim

  2. Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea

    Soo Jin Lee & Won Woo Lee

  3. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

    Jin Lim

  4. Division of Medical Oncology, Department of Internal Medicine, International St. Mary’s Hospital, College of Medicine, Catholic Kwandong University, Incheon, Republic of Korea

    Hyun Chang

  5. Department of Nuclear Medicine, Hanyang University Medical Center, Seoul, Republic of Korea

    Soo Jin Lee

Authors
  1. Hyun Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soo Jin Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jong Seok Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu Jung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Won Woo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jong Seok Lee or Won Woo Lee.

Ethics declarations

Conflict of interest

Author H.C. declares that he/she has no conflict of interest. Author S.J.L. declares that he/she has no conflict of interest. Author J.L. declares that he/she has no conflict of interest. Author J.S.L declares that he/she has no conflict of interest. Author Y.J.K declares that he/she has no conflict of interest. Author W.W.L declares that he/she has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

The requirement for informed consent was waived in view of the retrospective nature of the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chang, H., Lee, S.J., Lim, J. et al. Prognostic significance of metabolic parameters measured by 18F-FDG PET/CT in limited-stage small-cell lung carcinoma. J Cancer Res Clin Oncol 145, 1361–1367 (2019). https://doi.org/10.1007/s00432-019-02848-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-019-02848-9

Keywords

Search

Navigation